Abstracts Archive - Page 798 of 2607 - ACR Meeting Abstracts

Abstract Number: 1393 • ACR Convergence 2021
All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
Helen Keen¹, Warren Raymond², Susan Lester³, David Preen², Charles Inderjeeth⁴, Catherine Hill⁵ and Johannes Nossent², ¹University of Western Australia, Daglish, Australia, ²University of Western Australia, Perth, Australia, ³Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴University of Western Australia, Nedlands, Perth, Australia, ⁵Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Giant Cell Arteritis (GCA) is the most common primary vasculitis in high income countries and ischemic complications of GCA include blindness and stroke. The…
Abstract Number: 1394 • ACR Convergence 2021
Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. Prompt diagnosis and treatment of GCA is vital to prevent vision…
Abstract Number: 1395 • ACR Convergence 2021
Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients
Elisa Fernández-Fernández¹, Irene Monjo² and Eugenio De Miguel³, ¹Rheumatology department, La Paz University Hospital, Madrid, Spain, ²Hospital La Paz - IdiPAZ, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The implementation of fast track clinics (FTC) has enabled quick diagnosis and reduced the blindness rate of giant cell arteritis (GCA). Recently, the Southend…
Abstract Number: 1396 • ACR Convergence 2021
Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Matthew Koster¹, Cynthia Crowson², Rachel Giblon¹, Ali Duarte-Garcia¹, Jane Jaquith¹, Cornelia M. Weyand¹ and Kenneth Warrington³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, Minnesota
Background/Purpose: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and…
Abstract Number: 1397 • ACR Convergence 2021
Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
jigisha rakholiya¹, Matthew Koster¹, Hannah Langenfeld¹, Cynthia Crowson², Andy Abril³, Pankaj Bansal⁴, Lester Mertz⁵, Alicia Rodriguez Pla⁶, Rahul Sehgal⁴, Benjamin Wang⁷ and Kenneth Warrington⁸, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Eau Claire, WI, ⁵Mayo Clinic Arizona, Scottsdale, AZ, ⁶Mayo Clinic in Arizona, Scottsdale, AZ, ⁷Mayo Clinic, Jacksonville, FL, ⁸Mayo Clinic, Rochester, Minnesota
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory condition of medium- and large-sized arteries. Prospective clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1398 • ACR Convergence 2021
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
Alojzija Hocevar¹, Rok Jese¹, Jelka Kramaric², Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²UKC Ljubjana, Ljubjana, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
Abstract Number: 1399 • ACR Convergence 2021
Validation of a Giant Cell Arteritis Probability Score
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis. Failure to rapidly diagnose and treat patients with GCA can result in irreversible…
Abstract Number: 1400 • ACR Convergence 2021
Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study
Karin Wadström¹, Jan-Åke Nilsson¹, Aladdin Mohammad², Kenneth Warrington³, Eric Matteson⁴, Magnus Jakobsson², Lennart Jacobsson⁵ and Carl Turesson⁶, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵University of Gothenburg, Gothenburg, Sweden, ⁶Lund University, Malm, Sweden
Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
Abstract Number: 1401 • ACR Convergence 2021
Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
Sebastian Unizony¹, Maria C. Cid², Daniel Blockmans³, Elisabeth Brouwer⁴, Lorenzo Dagna⁵, Bhaskar Dasgupta⁶, Bernhard Hellmich⁷, Eamonn Molloy⁸, Carlo Salvarani⁹, Bruce Trapnell¹⁰, Kenneth Warrington¹¹, Ian Wicks¹², Manoj Samant¹³, Teresa Zhou¹³, Lara Pupim¹³ and John F Paolini¹³, ¹Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, ³General Internal Medicine, UZ Leuven, Leuven, Belgium, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Lombardia, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Internal Medicine, Rheumatology, and Immunology, Medius Kliniken, Kirchheim unter Teck, Germany, ⁸St Vincent's University Hospital, Dublin, Ireland, ⁹Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁰Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Cincinnati, ¹¹Mayo Clinic, Rochester, Minnesota, ¹²Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia, ¹³Kiniksa Pharmaceuticals Corp., Lexington, MA
Background/Purpose: Although giant cell arteritis (GCA) relapse is mostly defined by the recurrence of GCA signs/symptoms, in patients treated only with glucocorticoids, the C-reactive protein…
Abstract Number: 1402 • ACR Convergence 2021
Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy
Diana Prieto-Peña¹, Isabel Martínez-Rodríguez¹, Belén Atienza-Mateo², FRANCISCO JAVIER Gómez De La Fuente¹, Aida Sánchez-Salmón¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large vessel vasculitis (LVV)-Giant Cell Arteritis (LVV-GCA) (1-2). 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to assess…
Abstract Number: 1403 • ACR Convergence 2021
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Rafael B. Melero-González⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Joaquín M. Belzunegui¹⁰, Clara Moriano¹¹, Julio Sánchez¹², Judit Lluch¹³, Itziar Calvo¹⁴, Vicente Aldasoro¹⁵, Leticia León-Mateos¹⁶, Javier Loricera García¹⁷, Alberto Ruíz-Román⁵, Cristina Valero-Martínez¹⁸, Patricia Moya¹⁹, Marina Tortosa-Cabañas²⁰, Vanessa A. Navarro-Angeles⁶, Carles Galisteo²¹, Anne Riveros-Frutos²², Jose A. Román-Ivorra²³, Selene Labrada-Arrabal²⁴, Margarida Vasques-Rocha²⁵, Carlota L. Iñiguez-Ubiaga²⁶, María García-González²⁷ and Ricardo Blanco²⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁶Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario de La Princesa, Madrid, Spain, ¹⁹Hospital Sant Pau, Barcelona, Spain, ²⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ²¹Hospital Universitari Parc Tauli, Saadell, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁴Hospital del Mar, Barcelona, Spain, ²⁵Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁷Hospital Universitario de Canarias, La Laguna, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
Abstract Number: 1404 • ACR Convergence 2021
Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study
jigisha rakholiya¹, Mohanad Elfishawi¹, Tina Gunderson¹, Cynthia Crowson², Eric Matteson³, Carl Turesson⁴, Karin Wadström⁵, Cornelia Weyand¹, Matthew Koster¹ and Kenneth Warrington⁶, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Lund University, Malm, Sweden, ⁵Lund University, Malmö, Sweden, ⁶Mayo Clinic, Rochester, Minnesota
Background/Purpose: Advancing age, female sex and white race are well-known risk factors for development of giant cell arteritis (GCA). Recent studies suggest that certain metabolic…
Abstract Number: 1405 • ACR Convergence 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Lara Sánchez-Bilbao¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Eztizen Labrador²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario de la Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Hospital San Pedro, Logroño, La Rioja, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…
Abstract Number: 1406 • ACR Convergence 2021
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Jesús T. Sánchez-Costa¹, Rafael B. Melero-González², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Joaquín M. Belzunegui⁵, Clara Moriano⁶, Julio Sánchez⁷, Judit Lluch⁸, Itziar Calvo⁹, Vicente Aldasoro¹⁰, Lydia Abasolo¹¹, Javier Loricera¹², Alberto Ruíz-Román¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, María J. Garcia-Villanueva¹⁶, Vanessa A. Navarro-Angeles¹⁷, Carles Galisteo¹⁸, Anne Riveros-Frutos¹⁹, Jose A. Román-Ivorra²⁰, Selene Labrada-Arrabal²¹, Margarida Vasques-Rocha²², Carlota L. Iñiguez-Ubiaga²³, María García-González²⁴, Clara Molina-Almela²⁵, María Alcalde-Villar²⁶, Antonio Juan Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal¹³, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³¹, ¹Research unit, Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Basurto University Hospital, Bilbao, Spain, ¹⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Rheumatology Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries…
Abstract Number: 1407 • ACR Convergence 2021
Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles
Rosanne Reitsema¹, Lieske Wekema², Wayel Abdulahad¹, Peter Heeringa³, Minke Huitema¹, Maria Sandovici³, Annemieke Boots³, Elisabeth Brouwer³ and Kornelis van der Geest³, ¹Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common rheumatic inflammatory disease in the elderly. PMR is characterized by synovial inflammation of (peri)articular structures in the shoulders…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].